Lin C.-H.Lin M.-T.YAO-WEN KUOCHAO-CHI HO2021-08-242021-08-2420140169-5002https://www.scopus.com/inward/record.uri?eid=2-s2.0-84926420126&doi=10.1016%2fj.lungcan.2014.06.002&partnerID=40&md5=6d7dbda7c83b515089e8bbaaa1b6a5c1https://scholars.lib.ntu.edu.tw/handle/123456789/579295We report a patient with non-small cell lung cancer (NSCLC) developed leptomeningeal carcinomatosis (LMC) after 4 years of multiple treatments. High-dose tyrosine kinase inhibitor (TKI) was given for LMC at first but was not effective. She then received dual therapy combining of afatinib and cetuximab. Brain magnetic resonance imaging (MRI) showed a partial response of disease and the patient experienced a clinical benefit. Our case suggests that dual targeting of epidermal growth factor receptor (EGFR) by a combination of afatinib and cetuximab can be a potential novel treatment option in treating LMC when high-dose TKI failed. ? 2014 Elsevier Ireland Ltd.[SDGs]SDG3afatinib; bevacizumab; cetuximab; cisplatin; docetaxel; epidermal growth factor receptor; erlotinib; gefitinib; gemcitabine; paclitaxel; pemetrexed; protein tyrosine kinase inhibitor; afatinib; antineoplastic agent; cetuximab; epidermal growth factor receptor; monoclonal antibody; quinazoline derivative; adult; anisocoria; Article; brain metastasis; cancer chemotherapy; cancer radiotherapy; carcinomatous meningitis; case report; cytology; disease course; drug megadose; drug pulse therapy; dyspnea; female; headache; human; lung adenocarcinoma; neuroimaging; non small cell lung cancer; nuclear magnetic resonance imaging; pleura effusion; priority journal; treatment response; adenocarcinoma; brain; fatality; genetics; Lung Neoplasms; Meningeal Carcinomatosis; Meningeal Neoplasms; mutation; Neoplasms, Second Primary; pathology; secondary; Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain; Fatal Outcome; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Meningeal Neoplasms; Mutation; Neoplasms, Second Primary; Quinazolines; Receptor, Epidermal Growth Factorjournal article10.1016/j.lungcan.2014.06.002249990852-s2.0-84926420126